Medindia LOGIN REGISTER
Medindia
Advertisement

Novel Group of Drugs to Treat Ovarian Cancer

by Ramya Rachamanti on March 20, 2019 at 4:28 PM
Novel Group of Drugs to Treat Ovarian Cancer

New class of drugs called PARG inhibitors, can kill ovarian cancer cells by targeting weaknesses within their ability to copy their DNA, providing a potential new treatment option for ovarian cancer, according to the University of Manchester researchers.

The Cancer Research UK and Wellcome Trust funded study, published in the journal Cancer Cell

Advertisement


The first-in-class PARG inhibitor PDD00017273, was discovered in the Drug Discovery Unit at the Cancer Research UK Manchester Institute, part of The University of Manchester, as part of a targeted program to discover PARG inhibitors for the clinic.

This program is currently being progressed through a collaboration with IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies.
Advertisement

These findings are promising for patients diagnosed with ovarian cancer, the sixth commonest cause of cancer in women in the UK and causes more than 4,000 deaths each year.

"Sadly, for the majority of women diagnosed with ovarian cancer, the cancer relapses within 12 to 18 months of their first treatment, and so there is a pressing need to develop new therapies to treat this condition" said lead scientist Prof Stephen Taylor from The University of Manchester.

Through a collaborative effort across The University of Manchester including the Cancer Research UK Manchester Institute and The Christie , Manchester, scientists were able to screen ovarian cancer cells for specific genes that, when knocked out, would bring about PARG-inhibitor sensitivity. Through their work, the team identified the key genes that made cancer cells sensitive to PDD00017273 were those involved in DNA replication.

PhD student Nisha Pillay, provided valuable insight into how PARG inhibitors work. She said: "Before a cell divides, it must replicate its DNA. This critical process ensures the necessary amount of DNA is passed on to its daughter cells. Our research has shown that an inherent defect in the ability of an ovarian cancer cell to replicate its DNA can be exploited by the PARG inhibitor to kill the cancer cell".

"This new class of drugs is potentially very exciting and could signal a new way to help patients diagnosed with ovarian cancer in which their tumour has not responded to standard treatments".

The research team then went on to show that the PARG inhibitor can also be used in combination with other clinically accessible drugs, such as CHK1 and WEE1 inhibitors, to kill ovarian cancer cells that were taken directly from samples from patients treated at The Christie.

Dr. Robert Morgan, from The Christie, said: "We hope this work will provide further impetus for developing a PARG inhibitor for use in human trials, and also biomarkers that can be used to select the most appropriate patients to receive such treatments in the future"



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Women Health News

Persistent Health Issues for 1 in 3 New Mothers Post Childbirth
More than a third of women worldwide encounter persistent health concerns, such as depression, lower back pain, and various childbirth-related conditions.
Could Zinc Be the New Solution for Vaginal Yeast Infections?
New findings lead to advancements in treating vaginal yeast infections by offering fresh insights into how microbes within the body absorb zinc.
AI Tool Precisely Detects Postpartum Hemorrhage
An AI tool called Flan-T5 identified postpartum hemorrhage with 95% precision and detected 47% patients with the condition.
Active Scrutiny of Cervical Lesions Fuels Long-Term Cervical Cancer Risk
Active surveillance of cervical lesions was associated with higher cervical cancer risk in the long term compared to its removal.
Contraceptive Pills To Go Over-the-Counter Sale in Japan
Japan initiated the trial of selling morning-after contraceptive tablets over-the-counter in an effort to lower abortion rates and solace for rape victims.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Novel Group of Drugs to Treat Ovarian Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests